

Table 1. Results of base-case analysis among 5 screening strategies: screening using FIB-4 or VCTE were considered cost-effective with ICER within the willingness to pay threshold (USD50,000)

Strategy	Cost (USD)	Effectiveness (QALY)	Incremental cost (USD)	Incremental effect (QALY)	ICER (USD/QALY)	Label
No screening	20,610.72	11.91	-	-	-	undominated
FIB-4 screening	22,957.79	11.97	2,347.07	0.0638	36,799.87	extendedly dominated
FIB-4+VCTE simultaneous screening	23,401.46	11.98	443.68	0.00692	64,102.01	extendedly dominated
VCTE screening	23,453.16	12.03	2,842.45	0.115	24,727.23	undominated
FIB-4+VCTE Sequential screening	28,735.91	11.98	5,282.75	-0.0461	-114,623.44	absolutely dominated

FIB-4: fibrosis-4; ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year; VCTE: vibration-controlled transient elastography